Roche Holding AG 2022 AR2
The report outlines Roche's financial and non-financial performance for the fiscal year 2022, highlighting a 2% sales increase to CHF 63.3 billion. Key achievements include the launch of innovative treatments like Vabysmo for eye diseases and Lunsumio for blood cancer, alongside performing 29 billion diagnostic tests globally. In sustainability, the company reduced its total environmental impact per employee by 3.2% and achieved a 15.4% reduction in Scope 1 and 2 greenhouse gas emissions per employee compared to 2021. Additionally, Roche advanced its commitment to diversity and inclusion, reaching 37% of women in executive positions.
Company: Roche Holding AG
Sector: Manufacturing
Country: Switzerland
Year: 2022
Type: AR2
Pages: 220
Roche Holding AG
The report outlines Roche's financial and non-financial performance for the fiscal year 2022, highlighting a 2% sales increase to CHF 63.3 billion. Key achievements include the launch of innovative treatments like Vabysmo for eye diseases and Lunsumio for blood cancer, alongside performing 29 billion diagnostic tests globally. In sustainability, the company reduced its total environmental impact per employee by 3.2% and achieved a 15.4% reduction in Scope 1 and 2 greenhouse gas emissions per employee compared to 2021. Additionally, Roche advanced its commitment to diversity and inclusion, reaching 37% of women in executive positions.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Women on Board
Women in Management
Net Zero Target
Employees